Brose S, Autschbach R, Engel M, Rauch T, Rauch F W
Klinik für Thorax-, Herz- und Gefäßchirurgie, Klinikum RWTH Aachen, Pauwelstr. 30, 52074, Aachen, Germany,
Z Kardiol. 2001 Dec;90(Suppl 6):48-57. doi: 10.1007/s003920170008.
Since the first aortic valve replacement performed by Harken in 1960, the operation of aortic valve disease by replacing the native valve with a heart valve prosthesis has become one of the most frequently performed procedures in cardiac surgery. For valve replacement there are biological (xenografts and homografts) and mechanical heart valve prostheses available. When choosing the most suitable prosthesis the limited durability of a biological prosthesis and the risks of lifelong anticoagulation for a mechanical prosthesis have to be balanced.In this article the indication for operation of aortic valve stenosis and aortic regurgitation are discussed first. Based on the literature of the last 2 years the advantages and disadvantages of mechanical and biological heart valve prostheses (xenograft, homograft and ROSS procedure) are discussed. In addition rarely used techniques like aortic valve reconstruction are presented.Due to the fact that a biological prosthesis has a durability of 12-15 years and the risk of bleeding complications under anticoagulation grows with increasing age, the choice of a biological prosthesis can be recommended from the age of 65 years. Results of long-term studies at to whether this limit can be diminished by using a stentless biological prosthesis have to be awaited.
自1960年哈肯首次进行主动脉瓣置换术以来,用心脏瓣膜假体替换天然瓣膜治疗主动脉瓣疾病的手术已成为心脏外科最常开展的手术之一。对于瓣膜置换,有生物瓣膜(异种移植物和同种移植物)和机械心脏瓣膜假体可供选择。在选择最合适的假体时,必须权衡生物假体有限的耐用性和机械假体终身抗凝的风险。本文首先讨论主动脉瓣狭窄和主动脉瓣反流的手术指征。基于过去两年的文献,讨论了机械和生物心脏瓣膜假体(异种移植物、同种移植物和ROSS手术)的优缺点。此外,还介绍了很少使用的技术,如主动脉瓣重建。由于生物假体的耐用性为12至15年,且抗凝治疗下出血并发症的风险随年龄增长而增加,因此65岁以上可推荐选择生物假体。关于使用无支架生物假体是否可以降低这一年龄限制的长期研究结果还有待观察。